Antiviral activity of chitosan nanoparticles encapsulating silymarin (Sil–CNPs) against SARS-CoV-2 ( in silico and in vitro study)
Open Access
- 23 May 2022
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (25) , 15775-15786
Abstract
To develop a specific treatment against COVID-19, we investigated silymarin–chitosan nanoparticles (Sil–CNPs) as an antiviral agent against SARS-CoV-2 using in silico and in vitro approaches.Keywords
Funding Information
- Academy of Scientific Research and Technology
This publication has 42 references indexed in Scilit:
- Coronaviruses — drug discovery and therapeutic optionsNature Reviews Drug Discovery, 2016
- Does the Use of Chitosan Contribute to Oxalate Kidney Stone Formation?Marine Drugs, 2014
- Surface engineering of nanoparticles for therapeutic applicationsPolymer Journal, 2014
- Targeting silymarin for improved hepatoprotective activity through chitosan nanoparticlesInternational Journal of Pharmaceutical Investigation, 2014
- Anti-Viral Drugs for Human AdenovirusesPharmaceuticals, 2010
- Multiplexed Screening of Cellular Uptake of Gold Nanoparticles Using Laser Desorption/Ionization Mass SpectrometryJournal of the American Chemical Society, 2008
- Formulation and biopharmaceutical evaluation of silymarin using SMEDDSArchives of Pharmacal Research, 2007
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- Coronavirus as a possible cause of severe acute respiratory syndromeThe Lancet, 2003
- The Site of Attachment in Human Rhinovirus 14 for Antiviral Agents That Inhibit UncoatingScience, 1986